

Supplementary material

Genetic landscape of idiopathic pulmonary fibrosis: A systematic review, meta-analysis and epidemiological evidence of case-control studies

Pooja Singh^{1,5}, Debleena Guin^{3,5}, Bijay Patnaik^{2,4}, Ritushree Kukreti^{1,5*}

1. Academy of Scientific and Innovative Research (AcSIR), CSIR- Institute of Genomics and Integrative Biology (CSIR-IGIB) Campus, New Delhi, India
2. Centre of Excellence for Translational Research in Asthma and Lung Diseases, CSIR-Institute of Genomics and Integrative Biology, New Delhi, India
3. Department of Bioinformatics, Delhi Technological University, Shahbad Daulatpur, Main Bawana Road, New Delhi, India
4. Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences (AIIMS), New Delhi, India
5. Genomics and Molecular Medicine Unit, Institute of Genomics and Integrative Biology (IGIB), Council of Scientific and Industrial Research (CSIR), New Delhi, India

Correspondence

Ritushree Kukreti,

Genomics and Molecular Medicine Unit,

CSIR- Institute of Genomics and Integrative Biology,

Mall Road, Delhi 110 007, India.

Phone: 91-11-27662202; Fax: 91-11-27667471;

Email: ritus@igib.res.in, ritushreekukreti@gmail.com

Supplementary files:

1. **Supplementary Table 1:** PRISMA checklist
2. **Supplementary Fig. 1:** Two-stage search strategy to identify and select IPF gene association studies.
3. **Supplementary Table 2:** Literature search: MeSH terms used, individually and in combination, with AND/OR Boolean operators in Ist and IInd literature search strategy.
4. **Supplementary file 1:** Inclusion and exclusion criteria.
5. **Supplementary file 2:** Data extraction.
6. **Supplementary file 3:** Literature search and study selection.
7. **Supplementary Table 3:** Criteria for evaluation of epidemiological credibility.
8. **Supplementary Fig. 2:** PRISMA flow diagram for the inclusion and exclusion of studies exploring the role of genetic variants in IPF risk. The number of studies excluded on each step is represented as N.
9. **Supplementary Table 4:** Characteristics of included studies for assessment of the association between genetic variants and IPF susceptibility.
10. **Supplementary Table 5:** Details of quality assessment scoring for studies included in the meta-analysis based on modified Newcastle Ottawa Scale (NOS).
11. **Supplementary Table 6:** Summary of subgroup analysis findings based on ethnicity between IPF patients and healthy controls for genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), d) rs1800470 (*TGF-β1*).
12. **Supplementary Table 7:** Sensitivity analysis with pooled odds ratios (OR) for studies exploring the association of genetic variants with IPF susceptibility by removing one study each time.
13. **Supplementary Fig. 3:** Funnel plots showing publication bias among studies exploring IPF risk associated with genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), d) rs2076295 (*DSP*), e) rs12610495 (*DPP9*), f) rs1800470 (*TGF-β1*). Each point – represents a separate study for the indicated association or natural logarithm (log) of OR. A horizontal line means effect size.

Supplementary Table 1: PRISMA checklist


Section and Topic	Item #	Checklist item	Page No.
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	3
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	9(Supplementary file 1 of Supporting Information)
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	4, 7-8 (Table 2 of Supporting Information)
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	5, 9 (Supplementary file 2 of Supporting Information)
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were	9

Section and Topic	Item #	Checklist item	Page No.
		compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	(Supplementary file 2 of Supporting Information)
		10b List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	5
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	4,5
13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.		
13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.		
13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.		
13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).		
13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.		
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	6
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	5
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	6-7, Fig. 1, 9 (Supplementary file 3 of Supporting

Section and Topic	Item #	Checklist item	Page No.
			Information), 11 (Fig. 2 of Supporting Information)
		16b Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	8
Study characteristics	17	Cite each included study and present its characteristics.	7, 12-36 (Table 4 of Supporting Information), 24-35 (Table 1)
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	10, 42-43 (Fig. S2), 10, 40-41 (Table 7 of supporting information)
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	12-36 (Table 4 of Supporting Information)
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	23-34 (Table 1)
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	8-10, 35 (Table 2), 39 (Table 6 of Supporting Information)
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	8-10, 35 (Table 2)
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	10, 39-41 (Table 7 of Supporting Information)
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	10, 42-43 (Fig. 2)
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	10, 40-41 (Table 7 of supporting

Section and Topic	Item #	Checklist item	Page No.
			information)
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	11-13
	23b	Discuss any limitations of the evidence included in the review.	13-14
	23c	Discuss any limitations of the review processes used.	13-14
	23d	Discuss implications of the results for practice, policy, and future research.	14
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	4
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	NA
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	14
Competing interests	26	Declare any competing interests of review authors.	14
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	15

Supplementary Fig. 1: Two-stage search strategy to identify and select IPF gene association studies.



Supplementary Table 2: Literature search: MeSH terms used, individually and in combination, with AND/OR Boolean operators in Ist and IInd literature search strategy.

MeSH terms used for I st search strategy	
“idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”	
MeSH terms used for II nd search strategy	
rs35705950 (<i>MUC5B</i>)	“mucin5b”, “MUC5B”, “rs35705950”, “mucin”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”

rs2736100 (<i>TERT</i>)	“telomerase reverse transcriptase”, “TERT”, “rs2736100”, “telomerase related gene”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs2609255 (<i>FAM13A</i>)	“family with sequence similarity 13 member A”, “family with Sequence Similarity 13, Member A”, “FAM13A”, “rs2609255”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs2076295 (<i>DSP</i>)	“desmoplakin”, “desmoplakins”, “DSP”, “rs2076295”, “cell-cell adhesion”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs12610495 (<i>DPP9</i>)	“Dipeptidyl Peptidase 9”, “DPP9”, “rs12610495”, “DP9”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs1800470 (<i>TGF-β1</i>)	“TGF-beta1”, “TGF-beta-1”, “TGFbeta”, “transforming growth factor beta1”, “TGFB1”, “rs1800470”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs7934606 (<i>MUC2</i>)	“MUC2”, “mucin2”, “mucin-2”, “rs7934606”, “mucin”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs1278769 (<i>ATP11A</i>)	“ATP11A”, “ATPase Phospholipid Transporting 11A”, “rs1278769”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs5793295 (<i>LRRC34</i>)	“Leucine Rich Repeat Containing 34”, “Leucine-Rich Repeat-Containing 34”, “LRRC34”, “rs5793295”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”
rs111521887 (<i>TOLLIP</i>)	“TOLLIP”, “Toll Interacting Protein”, “rs111521887”, “Toll-Interacting Protein”, “genetics”, “genetic”, “gene”, “genetic variation”, “genetic variant”, “genetic factors”, “genetic association”, “SNP”, “single nucleotide polymorphism”, “polymorphism”, “idiopathic pulmonary fibrosis”, “idiopathic interstitial pneumonia”, “IPF”, “pulmonary fibrosis”

Supplementary file 1: Inclusion and exclusion criteria

Articles meeting the following criteria were eligible to be included in the study: (i) studies evaluating the association of genetic variants in IPF susceptibility, (ii) the study design must be a case-control design based on unrelated individuals, (iii) IPF patients must have been diagnosed by radiological, histopathological examination or based on American Thoracic Society (ATS)/ European Respiratory Society (ERS)/ Japanese Respiratory Society (JRS)/ Latin-American Thoracic Association (ALAT) diagnostic criteria. Articles were excluded based on the following criteria (i) review articles, meta-analysis, editorials, commentary, errata, and news articles, (ii) study design based on family or sibling pairs, (iii) non-human studies, (iv) non-English articles, (v) recruited IPF patients with comorbid conditions. Additionally, for meta-analyses, articles were excluded if (vi) insufficient data was provided for estimating odds ratios (OR) with 95% confidence interval (CI), (vii) the genotype distribution in controls was inconsistent with Hardy-Weinberg equilibrium (HWE).

Supplementary file 2: Data extraction

The following data were extracted: first author, year of publication, ethnicity of the studied population (where not conveyed, the country in which the study was carried out was considered), diagnostic criteria for IPF patients, number of participants (total and male/female), the mean age of cases and controls, genes, genetic variants, risk allele or genotype, statistical parameters [p-value, OR and 95% CI] of allelic model (for insufficient data for calculation, genotypic data is represented), genotyping methods used. Global allele frequency of risk allele was determined according to the dbSNP database (54). Authors were contacted where data required for conducting meta-analysis was not provided. Publications were excluded if responses were not received after two weeks. In the case of repeated or overlapping studies, the one with the most subjects and sufficient data was included.

Supplementary file 3: Literature search and study selection


Out of 4032 excluded studies, 908 studies were grey literature (Review, systematic review and meta-analysis), one study is in a language other than English, twenty-nine studies discussed IPF with comorbid condition, thirty studies were on familial IPF/pulmonary fibrosis (PF)/ idiopathic interstitial pneumonias (IIP) (as the current study focuses on sporadic IPF), 109 studies were conducted on animal or *in vitro* models for IPF, 1637 studies were not related to IPF, 1112 studies were related to IPF but do not talk about genetics, 104 non-genetic studies, nine studies talked about the genetics of IPF progression and survival, seventy-eight studies were related to therapeutics and drugs used in IPF, in twelve studies abstract was not found and three studies had non-significant results for the association of genetic variants and IPF susceptibility.

Supplementary Table 3: Criteria for evaluation of epidemiological credibility.

Criteria	Categories
Amount of evidence	A: Sample size* for the rarer allele in the meta-analysis is greater than 1000.
	B: Sample size* for the rarer allele in the meta-analysis is between 100-1000.
	C: Sample size* for the rarer allele in the meta-analysis is less than 100.
Replication	A: Extensive replication including at least one well-conducted meta-analysis, and similarity of phenotyping, genotyping and analytical models across studies.
	B: Well replicated without any conducted meta-analysis, and similarity of phenotyping, genotyping and analytical models across studies.
	C: No association, failed replication, and no independent replication.
Protection from bias	A: The summary effect size is greater than 1.15 or less than 0.87, and the following four situations do not occur: 1) nominal statistical significance is lost with the exclusion of the first published study; 2) nominal statistical significance is lost with the exclusion of studies where HWE is violated; 3) small study effects.
	B: There is no evidence of bias that would invalidate an association, but important information is missing
	C: The summary effect size is 0.87–1.15, or at least one of the following four situations occurs: 1) nominal statistical significance is lost with the exclusion of the first published study; 2) nominal statistical significance is lost with the exclusion of studies where HWE is violated; 3) small study effects.

*calculated by multiplying population specific minor allele frequency with total number of cases and controls included in meta-analysis. HWE, Hardy Weinberg equilibrium.

Supplementary Fig. 2: PRISMA flow diagram for the inclusion and exclusion of studies exploring the role of genetic variants in IPF risk. The number of studies excluded on each step is represented as N.



Supplementary Table 4: Characteristics of included studies for assessment of the association between genetic variants and IPF susceptibility.

Sl. No	Study Name (year)	Populati on/ Ethnicity	Diagnostic criteria	Sample characteristics								Gene	SNP	Risk allele/ genotyp e	OR (95% CI)	p-value	Method	Global allele frequency (risk allele)							
				Total (N)	Case			Control																	
					N	M/F	Age in years [mean±SD/ mean (range)]	N	M/F	Age in years [mean± SD /mean (range)]															
1	Dhindsa et al. (2021) ¹	European	ATS/ERS guideline s 2013	119,801	752	-	71.0	119,055	-	-		<i>MUC2</i>	rs7944723	C	1.86 (1.66- 2.07)	1.71×10^{-26}	Whole exome sequencing	0.122 “							
												<i>MUC5AC</i>	rs28403537	T	2.78 (2.35- 3.29)	6.96×10^{-26}		0.046 “							
												<i>MUC2</i>	rs6421972	T	1.41 (1.27- 1.55)	4.30×10^{-11}		0.390 “							
												<i>TOLLIP</i>	rs3750920	T	1.37 (1.24- 1.51)	9.63×10^{-10}		0.424 “							
												<i>MUC5B</i>	rs908229	C	0.75 (0.67- 0.82)	1.90×10^{-8}		0.443 “							
												<i>SPDL1</i>	rs116483731	A	2.87 (2.03- 4.07)	2.40×10^{-7}		0.006 “							
				198,014	1028	-	-	196,986	-	-		<i>SPDL1</i>	rs116483731	A	3.13 (2.37- 4.14)	1.00×10^{-15}		0.006 “							
2	Bonella et al. (2021) ²	Caucasian	ATS/ERS /JRS/AL AT guideline s 2011 and ATS/ERS /JRS/AL AT guideline s 2018	112	62	43/8	63.5±11	50	37/13	42.0±2		<i>MUC5B</i>	rs35705950	T	5.36 (2.46- 11.69)	<0.0001	RT-PCR using TaqMan	0.046							
3	Allen et al. (2020) ^{G3}	European	(ATS/ER S guideline s 2000 and ATS/ERS /JRS/AL AT	11259 ^D	2668	1818/80	(68.0±3.0/ 63.0±7.5) ^a , 66.0±9.5 ^b , (70/65.0) ^y	8591	4891/3,668	[542 ^a , [(240/270) ^a , 3,366] ^y		<i>KIF15</i>	rs78238620	A	1.58 (1.37- 1.83)	5.12×10^{-10}	Affymetrix 6.0 SNP array ^a ; Illumina Human 660W Quad BeadChip ^b ; Affymetrix UK BiLEVE	0.054							
					[541 ^a , 1,515 ^b , 612 ^y]	[55/1 ^a , 45 ^b , (103/0/48)]		[542 ^a , 4,683 ^b , 3,366] ^y	[542 ^a , [(240/270) ^a , 5/23]]		<i>MAD1L1</i>	rs12699415	A	1.28 (1.19- 1.37)	7.15×10^{-13}	0.409									
									<i>DEPTOR</i>		rs28513081	G	0.82 (0.76- 0.87)	1.20×10^{-9}	0.454										
									<i>RTEL1</i>		rs41308092	A	2.12 (1.67- 2.69)	7.65×10^{-10}	0.007										

	guidelines 2011 ^a ; ATS/ERS criteria 2002 ^b ; (ATS/ERS guidelines 2002 and ATS/ERS/JRS/AL AT guidelines 2011) ^y		5) ^b , (433/179) ^{y]}			88) ^b , (235/6/10/10) ^{y]}		<i>HECTD2</i>	rs537322302	G	7.82 (3.77-16.2)	3.43×10^{-8}	array(cases) ^y / Affymetrix UK BiLEVE and UK Biobank arrays(control) ^y	0.0002
								<i>RTEL1</i>	rs41308092	A	2.12 (1.67-2.69)	7.65×10^{-1}		0.008
								<i>LRRC34/TERC</i>	rs12696304	G	1.31 (1.21-1.40)	7.09×10^{-13}		0.470
								<i>FAM13A</i>	rs2013701	T	0.78 (0.74-0.84)	3.30×10^{-13}		0.499
								<i>TERT</i>	rs7725218	A	0.72 (0.67-0.77)	1.54×10^{-20}		0.408
								<i>DSP</i>	rs2076295	G	1.46 (1.37-1.56)	2.79×10^{-30}		0.432
								-	rs2897075	T	1.30 (1.21-1.38)	3.10×10^{-14}		0.310
								<i>MUC5B</i>	rs35705950	T	4.84 (4.37-5.36)	1.18×10^{-203}		0.046
								<i>ATP11A</i>	rs9577395	G	0.77 (0.71-0.83)	1.34×10^{-10}		0.166
								<i>IVD</i>	rs59424629	G	0.77 (0.71-0.82)	7.30×10^{-16}		0.480
								<i>AKAP13</i>	rs62023891	A	1.27 (1.18-1.36)	1.27×10^{-10}		-
								<i>MAPT</i>	rs2077551	C	0.71 (0.65-0.77)	2.83×10^{-16}		-
								<i>DPP9</i>	rs12610495	G	1.31 (1.22-1.42)	2.92×10^{-12}		0.183
	ATS/ERS/JRS/AL AT guidelines 2011 [^]	13330 ^R	1456 [792 [@] , 664 [^]] [(58/2/21/0) [@] , (488/176) ^y]	1,070/38 6 [(69/58) [@] , 68 [^]]	118 74 [10, 000 [@] , 1,87 4 [^]]	7,718 /4,15 6 [(721/ 0/ 2790) [@] , (508/ 1366) [^]]	-	<i>MAD1L1</i>	rs12699415	A	1.29 (1.18-1.41)	2.27×10^{-8}	Affymetrix UK Biobank and Spain Biobank arrays(cases) [@] ; Affymetrix UK BiLEVE and UK Biobank arrays(control) [@] ; HiSeq X Ten platform (Illumina) [^]	0.409
								<i>KIF15</i>	rs78238620	A	1.48 (1.24-1.77)	1.43×10^{-5}		0.054
								<i>DEPTOR</i>	rs28513081	G	0.87 (0.80-0.95)	0.002		0.454

	(ATS/ERS guidelines 2000 and ATS/ERS/JRS/AL AT guidelines 2011) ^a ; ATS/ERS guidelines 2002 ^b ; (ATS/ERS guidelines 2002 and ATS/ERS/JRS/AL AT guidelines 2011) ^c ; ATS/ERS/JRS/AL AT guidelines 2011 ^d	24589 ^M	288 8/11 95 412 4 [541 5) ^a , (103 0/48 1,51 5 ^b , 5) ^b , 612 ^y (433 /179) ^y , (582 /210) [@] , (488 /176) [^]] 792 @, 664 /210)^, (488 /176) [^]]	204 65 [54 /270) 2 ^a , (229 5/23 3 ^b , 88) ^b , 3,36 (235 6 ^y , 6/10 10,0 00 [@] , 1,87 4 [^]] 1366)^] -	12,60 9/ 7,824 [(240 /270) a, -	<i>KIF15</i>	rs78238620	A	1.54 (1.38-1.73)	4.05 × 10 ⁻¹⁴	Affymetrix 6.0 SNP array ^a ; Illumina Human 660W Quad BeadChip ^b ; Affymetrix UK BiLEVE array(cases)##;/Affymetrix UK BiLEVE and UK Biobank arrays (control) ^y ; Affymetrix UK Biobank and Spain Biobank arrays (cases) [@] , Affymetrix UK BiLEVE and UK Biobank arrays (control) [@] ; HiSeq X Ten platform (Illumina) [^]	0.054				
						<i>MADIL1</i>	rs12699415	A	1.28 (1.21-1.35)	9.38 × 10 ⁻²⁰		0.409				
						<i>DEPTOR</i>	rs28513081	G	0.83 (0.79-0.88)	1.93 × 10 ⁻¹¹		0.454				
						<i>RTEL1</i>	rs41308092	A	1.82 (1.51-2.19)	2.24 × 10 ⁻¹⁰		0.007				
4	Arimura-Omori et al. (2020) ⁴	Japanese	ATS/ERS/JRS/AL AT guidelines 2011	534	155 [include 7 families IPF] 113/42	74.0 (69-78)	379	283/96	58 (48-65)	<i>TERT</i>	rs2736100	T	1.75 (1.31-2.33)~	0.0001~	RT-PCR using TaqMan fluorescent probes	0.515
5	Moore et al. (2019) ⁵	non-Hispanic whites	ATS/ERS/JRS/AL AT guidelines 2018	7588	314 6	NA	NA	444 2	-	<i>TERC</i>	rs2293607	CT vs TT; CC vs TT	1.27 (1.15-1.41); 1.82 (1.50-1.41)	-	Deep sequencing (HiSeq 4000 sequencer)	0.269
										<i>FAM13A</i>	rs2609260	CT vs TT; CC vs TT	1.38 (1.25-1.54); 2.09 (1.65-2.64)	-		0.239
										<i>TERT</i>	rs4449583	CT vs CC; TT vs CC	0.66 (0.59-0.73); 0.47 (0.39-0.56)	-		0.323

8	Wang et al. (2019) ⁸	Chinese	ATS/ERS/JRS/AL AT guidelines 2018	279	79	68/11	64.2±8.86	200	NA	NA	<i>MUC5B</i>	rs868903	C	1.46 (1.01-2.13)~	0.042	PCR	0.489
											<i>TERT</i>	rs2853676	A	0.57 (0.33-0.98)~	0.041		0.251
9	Lorenzo-Salazar et al. (2019) ⁹	European-American	ATS/ERS/JRS/AL AT guidelines 2011 652 (60.8% samples were from Noth I. et al., 2013)	181	138/43	67.0	501	-	-	<i>MUC5AC</i>	rs371630624	C	1942(245.6-15360)	7.18×10^{-13}	HiSeq 2500 (Illumina, Inc.)	0.000	
											rs34474233	A	4.08 (2.56-6.49)	2.99×10^{-9}		0.022	
											rs34815853	A	4.01 (2.52-6.38)	4.15×10^{-9}		0.021	
										<i>MUC5B</i>	rs12802931	G	3.76 (2.73-5.16)	3.72×10^{-16}		0.073	
											rs35705950	T	6.18 (4.28-8.93)	2.69×10^{-22}		0.046	
										<i>MUC5B/RP11-532E4.2</i>	rs200243273	C	0.27 (0.17-0.43)	3.55×10^{-8}		0.294	
											rs4963073	G	3.23 (2.12-4.921)	4.91×10^{-8}		0.386	
										<i>CTD-224506.1</i>	rs4963072	G	3.34 (2.19-5.11)	2.63×10^{-8}		0.387	
											-	rs71469892	G	0.22 (0.15-0.31)	2.15×10^{-16}	0.232	
										<i>CTD-224506.2</i>	-	rs145898170	G	0.47 (0.36-0.62)	4.71×10^{-8}	-	
											-	rs199838022	C	0.45 (0.34-0.57)	7.14×10^{-9}	-	
										<i>rs1258685</i>	-	rs12586854	T	0.18 (0.12-0.26)	6.81×10^{-19}	0.455	
											-	rs11157543	C	0.13 (0.07-0.22)	5.97×10^{-14}	0.344	
										<i>rs1115754</i>	-	rs11157544	C	0.30 (0.21-0.41)	1.37×10^{-13}	0.436	
											-	rs12586856	G	0.18 (0.11-0.29)	3.77×10^{-13}	0.417	
										<i>rs1115754</i>	-	rs11157545	T	0.44 (0.34-0.59)	7.81×10^{-9}	0.522	
											-	rs183643415	A	0.04 (0.01-0.12)	2.77×10^{-8}	0.108	
										<i>rs1503228</i>	-	rs150322840	T	0.13 (0.07-0.24)	3.90×10^{-10}	0.151	
											-	rs8005465	A	0.37 (0.27-0.51)	4.41×10^{-10}	0.472	

								-	rs5434531 48	A	25.22 (8.29- 76.73)	1.30×10^{-8}		0.001	
								-	rs1289018 0	G	0.39 (0.28- 0.53)	2.91×10^{-9}		0.456	
								-	rs7325185 7	G	0.06 (0.02- 0.14)	9.59×10^{-10}		0.082	
								-	rs7141653	C	0.25 (0.17- 0.37)	1.65×10^{-11}		0.317	
								-	rs7145329	T	0.34 (0.24- 0.49)	2.59×10^{-9}		0.332	
								-	rs4900770	A	0.38 (0.28- 0.53)	9.10×10^{-9}		0.452	
								-	rs5873132 5	G	0.34 (0.25-0.47)	7.35×10^{-11}		0.495	
								<i>RP11-7- 7023.1</i>	rs1158115 19	C	4.93 (2.83- 8.58)	1.68×10^{-8}		0.191	
								<i>CTC- 501O10.1</i>	rs5638376 3	C	0.07 (0.03- 0.16)	1.75×10^{-9}		0.086	
								<i>CRHR1</i>	rs373417	T	0.10 (0.05- 0.20)	1.24×10^{-10}		0.086	
									rs7221124	A	0.04 (0.02- 0.09)	6.70×10^{-14}		0.359	
									rs5593813 6	A	151.90 (62.14- 371.50)	3.37×10^{-28}		0.309	
								<i>KANSL1</i>	rs1187084 4	A	3.98 (2.82- 5.62)	3.85×10^{-15}		0.333	
									rs3719965 25	A	0.04 (0.02- 0.11)	2.17×10^{-10}		0.135	
									rs1429202 72	C	0.10 (0.05- 0.21)	7.45×10^{-11}		0.185	
								<i>KANSL1/ LRRK37A</i>	rs2668637	G	5.32 (3.09- 9.13)	1.43×10^{-9}		0.037	
									rs2696618	C	6.74 (4.02- 11.31)	5.09×10^{-13}		0.173	
European	ATS/ERS criteria 2002 and ATS/ERS /JRS/AL AT guidelines 2011	3968 (samples from Allel et al., 2017)	602	426/176	70.0±8.4	336	2356.0/10 10.0	65±5.5	<i>MUC5AC</i>	rs3447423 3	A	3.15 (2.37- 4.21)	4.10×10^{-14}	Affymetrix Axiom UK BiLEVE array (Affymetrix) and Affymetrix Axiom UK Biobank array (Affymetrix)	0.022
										rs3481585 3	A	3.16 (2.37- 4.20)	4.13×10^{-14}		0.021
									<i>MUC5B</i>	rs1280293 1	G	2.42 (2.02- 2.90)	6.07×10^{-22}		0.073
										rs3570595 0	T	4.11 (3.31- 5.11)	1.86×10^{-37}		0.046
									<i>CTD- 224506.1</i>	rs4963072	G	1.29 (1.08- 1.54)	5.30×10^{-3}		0.387

10	Dresen et al. (2018) ¹⁰	Caucasian	ATS/ERS /JRS/AL AT guidelines 2011	3384	151 0	111 9/39 1	67.3±7.9	187 4	507/ 1367	56.38± 9.32	<i>CTC-501O10.1</i>	rs5638376 3	C	0.82 (0.68- 0.98)	2.42×10^{-2}	0.086 0.086 0.135 0.185 0.173	
											<i>CRHR1</i>	rs373417	T	0.82 (0.69- 0.98)	2.72×10^{-2}		
											<i>KANSL1</i>	rs3719965 25	A	0.80 (0.67- 0.95)	1.26×10^{-2}		
												rs1429202 72	C	0.83 (0.69- 0.98)	3.07×10^{-2}		
											<i>KANSL1/LRRC37A</i>	rs2696618	C	1.25 (1.05- 1.49)	1.05×10^{-2}		
											<i>MUC5B</i>	rs3570595 3	T	4.98 (4.40- 5.65)	<0.0001		
11	Daniil et al. (2018) ¹¹	European	ATS/ERS /JRS/AL AT guidelines 2018	244	40	34/6	68.8±8.3	204	-	-	<i>tRNA</i>	rs2835827 9*	C	18.96 (5.66- 63.52)~	<0.001	Illumina X10 sequence PCR	0.102 “ 0.022 “ 0.078 “ - 0.169 “ 0.028 “ - 0.007 “ - - 0.0002 “
											<i>ND3</i>	rs2835826 *	G	3.20 (1.26- 8.16)~	<0.001		
											<i>rs2835827</i>	8*	T	50.75 (6.14- 419.45)~	<0.001		
											<i>16S rRNA</i>	C3157T	T	91.56 (5.10- 1640.98)~	<0.001		
											<i>ND2</i>	rs3020602 *	C	63.36 (3.42- 1171.32)~	<0.001		
											<i>CYB</i>	G15884C	C	11.22 (1.98- 63.55)~	0.007		
											<i>COII</i>	G8251A	A	5.68 (1.56- 20.66)~	0.012		
											<i>16S rRNA</i>	A3136T	T	38.17 (1.93- 754.28)~	0.004		
											<i>CYB</i>	rs1603225 535*	T	26.55 (1.25- 564.09)~	0.026		
											<i>CD1C</i>	rs1475623 45	T	4.45 (2.47- 8.05)	2.90×10^{-6}	Affymetrix Axiom UK BiLEVE array (cases); Affymetrix	0.003
											<i>CFH</i>	rs5601050 94*/chr1: 196625450	G	3.27 (2.12- 5.04)	5.09×10^{-7}		0.0005(gnomAD)
12	Allen et al. (2017) ^{G12}	European	ATS/ERS guidelines 2002 and ATS/ERS	3968 _D	602	426/ 176	70.0±8.4	3,36 6	2356 /101 0	65.0±5 .5							

/JRS/AL AT guideline s 2011	<i>SRD5A2</i>	rs1910318 41	T	3.07 (2.21- 4.27)	1.80×10^{-10}	Axiom UK BiLEVE array and Affymetrix Axiom UK Biobank array (controls)	0.007
	<i>TTC27</i>	rs6726541	G	3.78 (2.62- 5.46)	1.42×10^{-12}		0.389
	-	rs7426632 4	A	0.45 (0.34- 0.59)	4.56×10^{-9}		0.284
	-	rs3393885 8	C	0.20 (0.10- 0.39)	3.61×10^{-9}		0.326
	-	rs555288 190*/chr 2:138817 685	G	47.8 (6.90-332)	1.65×10^{-6}		0.0005 (gnomAD)
	<i>FAM47E</i>	rs3436970 1	A	0.29 (0.16- 0.54)	3.73×10^{-6}		0.199
	-	rs2867396 8	C	0.47 (0.38- 0.58)	2.04×10^{-12}		0.472
	-	rs1128633 61	A	0.022 (0.001- 0.36)	1.60×10^{-9}		0.031
	<i>NDUFAF2</i>	rs1405074 20	G	2.98 (1.98- 4.48)	5.64×10^{-7}		0.007
	-	rs1506263 07	A	154 (21.0- 1136)	2.81×10^{-7}		0.000
	<i>DSP</i>	rs2076295	G	1.67 (1.44- 1.92)	4.14×10^{-12}		0.432
	<i>C6orf10</i>	rs9268159	T	0.43 (0.32- 0.58)	2.19×10^{-8}		0.185
	-	rs208501	T	1.83 (1.51- 2.22)	8.45×10^{-10}		0.183
	<i>FYN</i>	rs1409839	C	0.53 (0.42- 0.67)	1.10×10^{-7}		0.365
	<i>MRPL13</i>	rs5624537 23*/chr8:1 21446432	T	18.10 (6.07- 53.9)	6.69×10^{-7}		0.000
	-	rs1011763 9	C	25.30 (6.47- 98.8)	4.01×10^{-6}		0.112
	<i>MOB3B</i>	rs1180488 78	A	0.03 (0.002- 0.45)	1.50×10^{-7}		0.007
	<i>MOB3B</i>	rs1975503	C	0.15 (0.05- 0.44)	1.27×10^{-6}		0.117
	<i>REEP3</i>	chr10:6535 9362	T	36.40 (7.75- 172)	1.16×10^{-6}		-
	-	rs7762411 08*/chr10: 77228877	A	21.10 (6.25- 70.9)	7.53×10^{-7}		0.001 (gnomAD)

	Hispanic white ^b	ATS/ERS /JRS/AL AT guidelines 2011) ^a and ATS/ERS guidelines 2002 ^b		161 6 ^{bj}	7) ^a , (109 0/52 6) ^{bj}			468 3 ^{bj}	^a , (228 9/23 94) ^b]		<i>MUC5B</i>	rs3570595 0	T	2.46 (2.13- 2.85)	3.13×10^{-34}	Illumina 660 Quad beadchip ^b	0.046
										<i>AKAP13/KLHL25</i>	rs6202527 0	A	1.22 (1.11- 1.33)	9.96×10^{-6}		0.113	
13	European , American - European ^a and non-Hispanic white ^b	ATS/ERS guidelines 2000, ATS/ERS guidelines 2002 and ATS/ERS /JRS/AL AT guidelines 2011	1132 1 ^M	276 0 [602 ,	1,90 1/85 9 [(42 6/17 6), (385 /157) ^a , (109 0/52 6) ^{bj}	8,56 1 4 [(235 6/10 66, 10), (242/ 270) ^a , 468 3 ^{bj}	4,887 /367 4 [(235 6/10 66, 10), (242/ 270) ^a , 468 3 ^{bj}	65.0±5 .5, 63.0±7 .5 ^a	<i>DSP</i>	rs2076295	G	1.44 (1.35- 1.54)	7.81×10^{-28}	Affymetrix Axiom UK BiLEVE array (discovery cases); Affymetrix Axiom UK BiLEVE array and Affymetrix Axiom UK Biobank array (discovery controls), Affymetrix Genome-Wide Human SNP 6.0 Array ^a ; Illumina 660 Quad beadchip ^b	0.432		
										<i>MUC5B</i>	rs3570595 0	T	2.89 (2.56- 3.26)	1.12×10^{-66}			
										<i>AKAP13/KLHL25</i>	rs6202527 0	A	1.27 (1.18- 1.37)	1.32×10^{-9}			
14	Hirano et al. (2016) ¹⁴	Japanese	ATS/ERS criteria 2002	375	65	55/10	65.8±9.9	310	255/55	50.6±7.8	<i>FAM13A</i>	rs2609255	G	1.78 (1.29- 2.44)	<0.001	PCR	0.348
15	Yamaguchi et al. (2016) ¹⁵	Japanese	ATS/ERS /JRS/AL AT guidelines 2011	390	87	76/11	67.5±9.9	303	248/55	50.5±7.8	<i>AGER</i>	rs2070600	CT+TT vs CC	1.84 (1.08-3.1)	0.021	PCR	0.072

16	Kishore et al. (2016) ¹⁶	European	ATS/ERS criteria 2000, ATS/ERS criteria 2001 and ATS/ERS /JRS/AL AT guidelines 2011	261	165	125/40	67.9±11.60	96	45/51	34.5±8.94	<i>MUC5B</i>	rs35705950	T	5.23 (3.06-8.94)	1.80×10^{-11}	Sequenom MassARRAY platform integrating iPLEX® SBE reaction and MassARRAY® technology (Agena Bioscience, San Diego, CA, USA) based MALDI-TOF MS assay	0.046
											<i>IL-1α</i>	rs1800587	T	0.68 (0.99-0.46)	4.94×10^{-2}		-
											<i>TF</i>	rs1799899	A	2.06 (1.12-3.78)	1.87×10^{-2}		-
											<i>MUC2</i>	rs7934606	A	2.18 (1.50-3.16)	3.73×10^{-5}		0.380 “
17	Van der Vis et al. (2015) ¹⁷	Caucasian	ATS/ERS criteria 2002 and ATS/ERS criteria 2013 and ATS/ERS /JRS/AL AT guidelines 2011	364	115	97/18	63.5±11.0	249	-	-	<i>MUC5B</i>	rs35705950	T	3.60 (2.37-5.55)~	5.0×10^{-10}	TaqMan SNP genotyping assay (PCR)	0.046
18	Aquin o-Gálvez et al. (2015) ¹⁸	Mexican	ATS/ERS /JRS/AL AT guidelines 2011	373	168	103/65	64.5±11.0	205	36/169	47.0±5.4	<i>HSPA1B</i>	rs1061581	AA vs AG+GG	0.27 (0.13-0.57)	0.0003	5' nuclease SNP genotyping assays (PCR)	-
											<i>HSPA1A</i>	rs1043618	GG vs GC+CC	0.63 (0.41-0.97)	0.039		0.481
											<i>HSPA1L</i>	rs2227956	G	0.27 (0.10-0.75)	0.01		0.122
												rs2075800	CC vs TT	2.52 (1.32-4.81)	0.005		0.255
19	Peljto et al. (2015) ¹⁹	Mexican	ATS/ERS /JRS/AL AT guidelines 2011	194	83	59/24	66.0±7.7	111	-	-	<i>LRRC34</i>	rs6793295	C	2.24	0.01	-	0.421
											<i>FAM13A</i>	rs2609255	G	2.09	0.02		0.348
											<i>TERT</i>	rs2736100	C	0.50	0.05		0.484
											<i>MUC5B</i>	rs35705950	T	7.36	1.1×10^{-4}		0.046

20	Zhang et al. (2015) ²⁰	Han Chinese	ATS/ERS /JRS/AL AT guidelines 2011	368	102	45/57	59.3±9.87	266	137/129	56.7±1 2.80	<i>TOLLIP</i>	rs1115218 87	G	3.79	0.01	-	
											<i>IVD</i>	rs2034650	G	0.40	0.01	0.491	
		Korean		326	239	181/ 60	65.1±7.7	87	-	-	<i>IVD</i>	rs2034650	G	0.13	8.1×10 ⁻⁴	0.491	
21	Zhang et al. (2015) ²¹	Chinese	ATS/ERS /JRS/AL AT guidelines 2013	215	115	67/48	58.1±11.4	100	55/45	57.2±5 .5	<i>HLA-DRB1</i>	DRB1*08	DRB1*08	0.43 (0.19-0.96)	0.035	High resolution melting (HRM) method	-
											<i>IL-10</i>	rs1800896	G	1.80 (0.99-3.26)	0.05		0.272
22	Horim asu et al. (2015) ²²	Japanese	ATS/ERS criteria 2002	354	44	35/9	67.5±1.6	310	255/ 55	50.6±0 .4	<i>MUC5B</i>	rs3570595 0	T	1.62 (1.040-2.536)	0.034	PCR-RFLP	0.155
		German		106	71	51/20	67.6±1.2	35	15/20	44.3±2 .3	<i>MUC5B</i>	rs3570595 0	T	11.05 (3.30-36.99)	<0.001	PCR	0.046
23	Mathai et al. (2015) ²³	American	ATS/ERS /JRS/AL AT guidelines 2011	458	230	159/71	65.4 (64.2-66.5)	228	151/ 79	64.5 (63.7-65.4)	<i>DSP</i>	rs7282504 7	G	0.4 (0.19-0.85)~	0.0007	Illumina HiSeq platform	0.037
											<i>rs7282505</i> 4	C	0.4 (0.19-0.85)~	0.0003	0.037		
											<i>rs7282505</i> 8	T	0.40 (0.17-0.78)~	0.0005	0.038		
											<i>rs874646</i>	G	0.60 (0.34-0.89)~	0.002	0.256		
											<i>rs2744362</i>	C	0.60 (0.34-0.89)~	0.002	0.256		
											<i>rs2008748</i>	T	0.60 (0.34-0.89)~	0.001	0.745		
											<i>rs2744365</i>	G	0.60 (0.34-0.89)~	0.002	0.230		
											<i>rs2237102</i>	C	0.60 (0.34-0.89)~	0.002	0.245		
											<i>rs2237103</i>	G	0.60 (0.34-0.89)~	0.002	0.250		
											<i>rs2237104</i>	T	0.60 (0.34-0.89)~	0.002	0.246		

24	Jiang et al. (2015) ²⁴	Han Chinese	ATS/ERS criteria 2002	437	187	138/49	69.7±4.3	250	172/78	67.7±7.3	<i>MUC5B</i>	rs2078438	A	0.60 (0.34-0.89)~	0.002	0.230		
													rs2744368	T	0.60 (0.34-0.89)~	0.002	0.233	
													rs2744369	T	0.60 (0.34-0.89)~	0.001	0.234	
													rs2744370	C	0.60 (0.34-0.89)~	0.002	0.236	
													rs2744371	C	0.60 (0.34-0.89)~	0.002	0.234	
													rs2744372	G	0.60 (0.34-0.89)~	0.002	0.249	
													rs2744374	T	0.60 (0.34-0.89)~	0.002	0.250	
													rs2744373	A	0.50 (0.34-1.04)~	0.004	0.108	
													rs2744375	T	0.50 (0.34-1.04)~	0.004	0.146	
													rs1713351 ₂	A (insertion)	1.70 (1.05-2.96)~	0.004	0.199	
													rs1451252 ₈₆	C (deletion)	0.50 (0.34-1.04)~	0.003	0.116	
													rs2008756	G	0.60 (0.34-0.89)~	0.0009	0.246	
													rs2237105	A	0.60 (0.34-0.89)~	0.002	0.230	
													rs2744371	C	0.77 (0.66-0.91)	0.002	TaqMan genotyping assays	0.234
													rs2744373	A	0.80 (0.66-0.98)	0.03		0.108
													rs2076295/ 6p24	G	1.36 (1.19-1.56)	<0.001		0.432
24	Jiang et al. (2015) ²⁴	Han Chinese	ATS/ERS criteria 2002	437	187	138/49	69.7±4.3	250	172/78	67.7±7.3	<i>MUC5B</i>	rs3570595 ₀	T	1.93 (1.32-2.82)	0.0007	TaqMan probe-based SNP genotyping	0.046	
25	Wang et al. (2014) ²⁵	Chinese	ATS/ERS /JRS/AL AT guidelines 2011	1178	165	101/64	61.8±12.7 ₂	101 ₃	525/ 488	58.6±1 2.72	<i>MUC5B</i>	rs3570595 ₀	T	4.33 (1.99-9.42)	0.001	PCR-RFLP and TaqMan probe-based SNP genotyping	0.046	
				485	80 (male and	-	-	405 (male and	-	-	<i>MUC5B</i>	rs3570595 ₀	T	10.48 (2.60-42.36)	0.001		0.046	

					>=55 y)			>=55 y)									
26	Uh et al. (2014) ²⁶	Korean	ATS/ERS guideline s 2002	420	237	163/74	62.0(31-83)	183	55/128	61.0(50-81)	<i>ADAM33</i>	rs628977	AA vs AG+GG	0.50 (0.27-0.94)	0.03	Single-Base Extension (SBE)	0.341
				345	162	surgical IPF	112/50	59.0(31-83)	183	55/128	61.0(50-81)	<i>ADAM33</i>	rs628977	AA vs AG+GG	0.40 (0.19-0.84)	0.02	0.341
27	Sangiolo et al. (2014) ²⁷	Italian	ATS/ERS /JRS/AL AT guideline s 2011	196	89	67/22	68.8±7.6	107	105/2	54.3±4.3	<i>HFE</i>	rs1799945*	GC	2.60 (1.35-5.02)	0.004**	reverse dot blot	0.073
28	Coghlan et al.(2014) ²⁸	Mixed, European (90% Caucasian, 5% African-American, 3% Asian and 2% Hispanic)	ATS/ERS /JRS/AL AT guideline s 2011	324	132	98/34	54.6±9.2	192	99/93	60.2±8.1	<i>MUC5B</i>	rs35705950	T	2.67 (1.78-4.01)	<0.0001	NGS	0.046
29	Ohshima et al. (2014) ²⁹	German	-	127	42	-	-	85	-	-	<i>ANGPT2</i>	rs2515475	T	-	0.048	RT-PCR	0.0132
30	Fingerlin et al. (2013) ^{G 30}	non-hispanic white	ATS/ERS guideline s 2002	6299 ^b	1616	1090/526	65.5±9.5	4683	2289/2394	-	<i>TERT</i>	rs2736100	C	0.73 (0.67-0.79)	7.60×10^{-14}	Illumina Human 660W Quad BeadChip	0.484
											<i>DSP</i>	rs2076295	G	1.43 (1.32-1.55)	1.14×10^{-16}		0.432
											-	rs4727443	A	1.30 (1.20-1.41)	6.72×10^{-9}		0.381
											<i>MUC2</i>	rs7934606	C	1.52 (1.40-1.65)	5.46×10^{-22}		0.380 “
											-	rs2034650	G	0.77 (0.71-0.84)	1.86×10^{-9}		0.491
											<i>MAPT</i>	rs1981997	A	0.71 (0.64-0.78)	2.52×10^{-8}		0.087
											<i>DPP9</i>	rs12610495	G	1.29 (1.18-1.41)	9.57×10^{-9}		0.183
											-	rs3778337	A	1.31(1.20-1.43)	6.41×10^{-9}		0.303
											-	rs1379326	C	1.78 (1.45-2.19)	5.74×10^{-9}		0.329

							-	rs7942850	C	1.38 (1.27-1.50)	9.29×10^{-14}	0.315
							-	rs6421972	T	1.51 (1.39-1.64)	1.62×10^{-21}	0.390
							-	rs7480563	C	0.69 (0.64-0.75)	4.17×10^{-18}	0.697
							-	rs4077759	C	0.74 (0.67-0.80)	8.47×10^{-13}	0.484
							-	rs868903	T	0.64 (0.59-0.70)	1.26×10^{-22}	0.510
							-	rs2334659	A	0.71 (0.63-0.80)	4.71×10^{-9}	0.061
							-	rs7122936	C	0.76 (0.69-0.82)	3.69×10^{-8}	0.346
							-	rs1992272	T	0.78 (0.71-0.85)	3.49×10^{-8}	0.271
							-	rs17563986	G	0.71 (0.64-0.78)	3.39×10^{-8}	0.086
							-	rs807023	G	0.71 (0.64-0.79)	1.22×10^{-8}	0.773
							-	rs2109069	A	1.28 (1.18-1.40)	3.87×10^{-8}	0.211
2766 R	876	599/277	63.4±9.7	1890	907/983	58.4±9.7	<i>TERT</i>	rs2736100	C	0.74 (0.65-0.83)	4.05×10^{-7}	0.484
							<i>DSP</i>	rs2076295	T	1.26 (1.13-1.42)	6.28×10^{-5}	0.432
							<i>MUC2</i>	rs7934606	C	1.56 (1.39-1.76)	1.49×10^{-13}	0.380 “
							-	rs2034650	G	0.82 (0.74-0.93)	0.00098	0.491
							<i>MAPT</i>	rs1981997	A	0.67 (0.58-0.79)	4.74×10^{-7}	0.087
							<i>DPP9</i>	rs12610495	G	1.30 (1.15-1.47)	3.94×10^{-5}	0.183
9065 M	2492	1689/803	-	6573	3196/3377	-	<i>TERT</i>	rs2736100	C	-	1.71×10^{-19}	0.503
							<i>DSP</i>	rs2076295	T	-	1.08×10^{-19}	0.432
							-	rs4727443	A	-	1.17×10^{-8}	0.381
							<i>MUC2</i>	rs7934606	C	-	6.87×10^{-34}	0.38 “
							-	rs2034650	G	-	9.76×10^{-12}	0.491
							<i>MAPT</i>	rs1981997	A	-	8.87×10^{-14}	0.087
							<i>DPP9</i>	rs12610495	G	-	1.68×10^{-12}	0.183
												Multiplex (Sequenom) iPLEX and uniplex (TaqMan) assays

								<i>LRRC34</i>	rs6793295	C	-	8.33×10^{-13}		0.421		
								<i>FAM13A</i>	rs2609255	G	-	2.20×10^{-11}		0.348		
								<i>OBFC1</i>	rs1119186 5	A	-	2.44×10^{-8}		0.397		
								<i>ATP11A</i>	rs1278769	A	-	6.72×10^{-9}		0.233		
								<i>MUC5B</i>	rs3570595 0	T	4.51 (3.91- 5.21)	7.21×10^{-95}		0.046		
31 Noth et al. (2013) G31	European - American (617) and non-European - American (16)	ATS/ERS guideline s 2000 and ATS/ERS /JRS/AL AT guideline s 2011	1084 D	542	385/ 157	67.0(61- 73)	542	-	63.0(4 0-70)	<i>SLC35F3</i>	rs1181045 2	G	-	6.31×10^{-6}	Genome-Wide Human SNP 6.0 Array	0.230
										<i>rs1275046</i> 7	A	1.55 (1.25- 1.93)	6.31×10^{-5}	0.071		
										<i>ARHGEF4</i>	rs1303456 2	G	-	6.31×10^{-5}	0.555	
										<i>rs6652575</i> 1	A	1.79 (1.36- 2.35)	7.94×10^{-6}	0.064		
										<i>ABCG2</i>	chr4:89147 344	-	7.36 (2.37- 22.9)	1.58×10^{-6}	-	
										<i>rs1006511</i> 1	T	1.57 (1.28- 1.93)	1.58×10^{-5}	0.196		
										<i>rs7449198</i>	A	1.65 (1.33- 2.04)	1.26×10^{-6}	0.132		
										<i>rs5860873</i> 9	A	0.32 (0.18- 0.56)	6.31×10^{-6}	0.144		
										<i>rs6862667</i>	G	0.32 (0.17- 0.59)	7.94×10^{-5}	0.208		
										<i>rs5594814</i> 6	G	0.66 (0.79- 0.55)	2.00×10^{-6}	0.437		
										<i>rs6977733</i>	A	0.67 (0.56- 0.80)	1.00×10^{-5}	0.315		
										<i>rs3800917</i>	A	0.67 (0.56- 0.08)	7.94×10^{-6}	0.302		
										<i>K03193</i>	rs7679539 8	G	2.36 (1.54- 3.63)	1.00×10^{-5}	0.014	
										<i>rs7984289</i> 6	C	2.49 (1.61- 3.85)	7.94×10^{-6}	0.014		
										<i>rs1131722</i> 95	T	-	7.94×10^{-6}	0.054		
										<i>COLIA2</i>	rs2293739	A	0.63 (0.48- 0.82)	3.98×10^{-4}	0.063	
										<i>MYOM2</i>	rs1775147 1	A	1.56 (1.24- 1.97)	2.51×10^{-5}	0.105	
										<i>rs6558599</i>	G	1.87 (2.48- 1.41)	7.94×10^{-6}	0.112 “		

	<i>PPP2R2A</i>	rs1425735	A	1.45 (1.76-1.20)	1.00×10^{-4}	0.470
<i>LRP12</i>	rs4291236	C	1.78 (2.45-1.30)	1.58×10^{-4}	0.029	
	rs4537272	C	-	2.00×10^{-6}	0.017	
-	rs13802044 3*/ chr9:253562 16	T	10.27 (2.24-46.6)	7.94×10^{-6}	0.003	
	rs15104577 8*/ chr9:253705 76	T	-	1.26×10^{-5}	0.004	
<i>MUC5B</i>	rs3570595 0	T	1.57 (1.20-2.05)	6.31×10^{-6}	0.046	
-	rs1104113 3	G	0.81 (0.96-0.68)	1.00×10^{-2}	0.524	
-	rs7481967	C	0.98 (1.25-0.77)	7.94×10^{-1}	0.324	
<i>TOLLIP</i>	rs5744033	G	-	1.26×10^{-6}	0.927	
	rs3168046	C	1.24 (1.05-1.47)	1.00×10^{-2}	0.563	
	rs3829223	C	0.83 (0.99-0.70)	2.51×10^{-2}	0.501	
	rs3750920	T	1.25 (1.06-1.48)	5.01×10^{-3}	0.360	
	rs5743961	A	0.82 (0.55-1.21)	2.51×10^{-1}	0.048	
	rs1115218 87	G	1.54 (1.26-1.87)	5.01×10^{-7}	0.072	
	rs908225	T	0.75 (0.91-0.62)	2.51×10^{-3}	0.376	
	rs5743944	A	0.69 (0.56-0.85)	1.58×10^{-4}	0.148	
	rs5743942	C	0.88 (0.75-1.05)	1.00×10^{-1}	0.338	
	rs5743905	C	0.82 (0.55-1.21)	2.51×10^{-1}	0.047	
	rs5743900	G	0.69 (0.55-0.86)	3.16×10^{-4}	0.930	
	rs5743899	G	0.90 (1.12-0.72)	3.16×10^{-1}	0.339	
	rs5743894	G	1.58 (1.30-1.93)	1.26×10^{-7}	0.074	

								<i>TOLLIP</i>	rs5743894	G	1.19 (0.94-1.50)	1.57×10^{-1}		0.074	
								<i>TOLLIP</i>	rs5743890	G	0.60 (0.45-0.80)	3.49×10^{-4}		0.047	
								<i>SPP12C</i>	rs17690703	T	0.78 (0.62-0.98)	3.07×10^{-2}		0.123	
									rs4277405	CC vs CT+TT	2.16 (1.35-3.45)	0.001		0.354	
									rs4459609	CC vs CA+AA	2.09 (1.30-3.38)	0.003		0.353	
									rs1800764	CC vs CT+TT	1.93 (1.21-3.07)	0.006		0.533	
									rs4291	TT vs AT+AA	1.72 (1.07-2.78)	0.03		0.348	
									rs4292	CC vs CT+TT	1.86 (1.16-2.98)	0.01		0.256	
									rs4309	CC vs CT+TT	1.72 (1.09-2.71)	0.02		0.576	
									rs4311	TT vs CT+CC	1.74 (1.06-2.85)	0.03		0.334	
									rs4343	GG vs GA+AA	1.73 (1.07-2.79)	0.03		0.356	
									rs4351	GG vs AG+AA	1.86 (1.16-2.99)	0.01		0.439	
									rs1055086	AA vs AG+GG	1.69 (1.10-2.59)	0.02		0.342	
									(+)-21288_i nsdel	-	1.84 (1.18-2.86)	0.008		-	
									rs4277405	CC vs CT+TT	2.00 (1.31-3.06)	0.001		0.354	
									rs4459609	CC vs CA+AA	1.97 (1.28-3.04)	0.002		0.353	
									rs1800764	CC vs CT+TT	1.83 (1.20-2.77)	0.005		0.533	
									rs4291	TT vs AT+AA	1.66 (1.08-2.56)	0.02		0.348	
									rs4292	CC vs CT+TT	1.79 (1.17-2.74)	0.007		0.256	
									rs4309	CC vs CT+TT	1.71 (1.14-2.58)	0.01		0.576	
									rs4311	TT vs CT+CC	1.78 (1.15-2.78)	0.01		0.334	
									rs4343	GG vs GA+AA	1.70 (1.10-2.62)	0.02		0.356	
32	Uh et al. (2013) ³²	Korean	ATS/ERS guidelines 2002	676	220	153/67	62.0(50-83)	456	278/178	63.0(50-87)				Single base extension (SBE)	
				607	151 (sur gical IPF)	105/46	59.0(50-83)	456	278/178	63.0(50-87)					

													rs4351	GG vs AG+AA	1.81 (1.19-2.76)	0.006		0.439
													rs1055086	AA vs AG+GG	1.68 (1.15-2.46)	0.007		0.342
													(+) ^{21288_i} nsdel	-	1.62 (1.08-2.43)	0.02		-
33	Wei et al. (2013) ³³	American whites	ATS/ERS guidelines 2002	773	84	55/29	64.4±7.7	689	360/329	55.7±13.2	<i>MUC5B</i>	rs35705950	T	3.20 (2.21-4.63)	1.16×10^{-10}	TaqMan SNP genotyping assay (PCR)	0.046	
34	Stock et al. (2013) ³⁴	UK Caucasian	ATS/ERS criteria 2000 and ATS/ERS guidelines 2002	526	110	79/31	64.6(45-85)	416	-	-	<i>MUC5B</i>	rs35705950	T	4.90 (3.42-7.03)	2.04×10^{-17}	TaqMan SNP genotyping assay (PCR)	0.046	
35	Borie et al. (2013) ³⁵	Caucasian (Europeans-82%; North African-14%; Black-4%)	ATS/ERS guidelines 2000	1525	142	116/26	69.8±8.9	1383	-	-	<i>MUC5B</i>	rs35705950	T	5.19 (3.56-7.58)~	2.0×10^{-44}	TaqMan SNP genotyping assay (PCR)	0.046	
36	Son et al. (2013) ³⁶	Korean	ATS/ERS guidelines 2002	170	85 surgical IPF	55/30	61.0±8	85	55/30	59.0±8	<i>TGF-β1</i>	rs1800470	TT vs TC+CC	2.10 (1.1-4.0)	0.028	PCR-RFLP	0.540	
37	Martinelli et al. (2013) ³⁷	Italian	ATS/ERS /JRS/ALAT guidelines 2011	113	32	17/13	68.2±9.7	81	43/38	68.0±12.6	<i>TCN2</i>	rs1801198	G	1.83 (1.02-3.29)	0.04	PCR-RFLP	0.420	
38	Yadong et al. (2013)	Chinese	-	184	84	-	-	100	-	-	<i>ACE</i>	insertion/deletion polymorphism	Deletion	-	<0.05	PCR-RFLP	-	
39	Korthagen et al. (2012) ³⁸	Netherlands	ATS/ERS criteria 2002	430	77	58/19	60.8±13.6	353	139/210	39.2±12.4	<i>CDKN1A</i>	rs2395655	G	1.61 (1.13-2.28)~	0.007~	Illumina GoldenGate bead SNP assay	0.527	
												rs733590	C	1.52 (1.07-2.17)~	0.01~		0.406	
												rs730506	C	1.52 (1.03-2.24)~	0.032~		0.218	
												rs3176352	C	0.60 (0.41-0.87)~	0.007~		0.496	

40	Zhang et al. (2012) ³⁹	Han Chinese	ATS/ERS criteria 2000	11,9 91	36	24/1 2	63.4±5.1	119 55	8129 /382 6	48.3±12 .1	<i>HLA-A</i>	HLA-A*03	HLA-A*03	-	0.002	PCR-SSP	-
				11,9 86	31	-	-	11,9 55	-	-	<i>HLA-B</i>	HLA-B*14	HLA-B*14	-	<0.0001		-
				11,9 86	31	-	-	11,9 55	-	-	<i>HLA-B</i>	HLA-B*15	HLA-B*15	-	<0.0001		-
				11,9 86	31	-	-	11,9 55	-	-	<i>HLA-B</i>	HLA-B*40	HLA-B*40	-	<0.0001		-
				11,9 86	31	-	-	11,9 55	-	-	<i>HLA-A</i>	HLA-A*03	HLA-A*03	-	0.0013		-
				11,9 86	31	-	-	11,9 55	-	-	<i>HLA-B</i>	HLA-B*15	HLA-B*15	-	<0.0001		-
				11,9 86	31	-	-	11,9 55	-	-	<i>HLA-B</i>	HLA-B*40	HLA-B*40	-	<0.0001		-
				11,9 86	31	-	-	11,9 55	-	-							
41	Zhang et al. (2011) ⁴⁰	Non-Hispanic Whites	ATS/ERS criteria 2002**	412	246	163/83	67.4±9.0	166	71/9 5	48.7±16 .1	<i>MUC5B</i>	rs3570595 0	T	4.18 (2.82- 6.20)	<0.0001	TaqMan SNP genotyping assay (PCR)	0.046
		Non-Hispanic Whites		731	95	75/20	69.2±8.4	636	365/ 271	53.7±14 .1	<i>MUC5B</i>	rs3570595 0	T	4.43 (3.14- 6.25)	<0.0001		0.046
42	Ahn et al. (2011) ⁴¹	Korean	ATS/ERS criteria 2000	618	237	163/74	61.0(41- 83)~	456	278/ 178	62.0(5 0-87)	<i>IL8</i>	rs4073	AA vs AT+TT	0.46 (0.26- 0.80)	0.006	TaqMan SNP genotyping assay (PCR)	0.522
											<i>IL8</i>	rs2227307	GG vs GT+TT	0.48 (0.28- 0.82)	0.007		0.423
				330	152 (males)	-	-	178 (males)	-	-	<i>IL8</i>	rs4073	AA vs AT+TT	0.51 (0.26- 0.97)	0.04		0.522
											<i>IL8</i>	rs2227307	GG vs GT+TT	0.49 (0.26- 0.93)	0.03		0.423
43	Seibold et al. (2011) ⁴²	Caucasian	ATS/ERS criteria 2000 and ATS/ERS guidelines 2002	814	492	352/ 140	67.2±8.1	322	147/ 175	60.3±1 2.6	<i>MUC2</i>	rs1090208 1	TT vs CC	0.70 (0.5-0.8)	4.3×10^{-4}	Sequenom iPLEX assay	0.450 “
											<i>MUC2</i>	rs4145334 6	TT vs CC	2.80 (1.6-5.2)	0.001		0.008
											<i>MUC2</i>	rs4148034 8	AA vs GG	0.50 (0.4-0.8)	0.001		0.031
											<i>MUC5AC</i>	rs9667239	TT vs CC	1.90 (1.4-2.7)	5.6×10^{-4}		0.101
											<i>MUC5AC</i>	rs5584650 9	AA vs GG	3.60 (1.7-7.3)	0.001		0.007
											<i>MUC5AC</i>	rs2840353 7	TT vs CC	4.60 (2.8-7.6)	3.2×10^{-9}		0.059 “
											<i>MUC5AC</i>	rs3528896 1	TT vs GG	2.00 (1.5-2.6)	3.7×10^{-6}		0.100
											<i>MUC5AC</i>	rs3567122 3	TT vs CC	1.50 (1.2-1.9)	0.001		0.257

	Xue et al. (2011) ⁴³	Caucasian	ATS/ERS criteria 2000	150	96	61/35	65.0±8	54	18/36	304	-	-	<i>MUC5B</i>	rs2865423 2	TT vs CC	0.60 (0.5-0.8)	1.1×10^{-4}	0.375		
														rs2672794	TT vs CC	0.50 (0.4-0.7)	1.9×10^{-7}	0.313		
														rs3570595 0	TT vs GG	8.30 (5.8-11.9)	4.6×10^{-31}	0.046		
														rs1280400 4	TT vs GG	0.60 (0.5-0.8)	1.2×10^{-4}	0.560		
														<i>MUC5B</i>	rs3561954 3	TT vs GG	2.10 (1.6-2.8)	1.5×10^{-8}	0.226	
														rs868903	CC vs TT	1.60 (1.3-2.1)	2.8×10^{-5}	0.489		
														<i>MUC5AC</i>	MUC5AC-025447	TT vs CC	1.60 (1.2-2.2)	0.003	-	
														<i>MUC2</i>	rs7934606	TT vs CC	1.70 (1.4-2.2)	3.8×10^{-6}	0.380 “	
														rs1090208 9	GG vs AA	1.50 (1.2-1.9)	2.9×10^{-4}	0.492 “		
														rs7127117	CC vs TT	1.60 (1.3-2.0)	6.9×10^{-5}	0.520		
														-	rs3459590 3	TT vs CC	0.50 (0.4-0.7)	2.4×10^{-6}	0.267	
	Barlo et al. (2011) ⁴⁴	Caucasian	ATS/ERS criteria 2002	426	77	58/19	60.8±13.6	349	139/210	39.2±12.4	<i>ILRN</i>	rs2637988	G	<i>MUC5AC</i>	rs436734 8	A	0.60 (0.3-1.0)	<0.05	PCR followed by cycle sequencing reactions at 1/64 Big Dye reaction scale	0.031
														rs7104590	C	0.50 (0.3-0.9)	<0.05	0.357 “		
														rs1090208 1	T	1.70 (1.0-2.9)	<0.05	0.450 “		
														rs1241687 3	A	0.40 (0.2-0.8)	<0.01	0.361		
														MUC5AC-022675	T	4.60 (1.0-42.6)	<0.05	-		
														MUC5AC-026495	C	0.50 (0.2-1.0)	<0.05	-		
														rs3528896 1	T	2.30 (1.2-4.8)	<0.01	0.100		
44	Xue et al. (2011) ⁴³	Caucasian	ATS/ERS criteria 2000	560	275	73/202	66.0±1	285	-	-	<i>HLA-DRB1</i>	HLA-DRB1*1501	HLA-DRB1*1501	1.85 (1.31-2.62)~	0.0005~	PCR-SSP	-			
45	Barlo et al. (2011) ⁴⁴	Caucasian	ATS/ERS criteria 2002	426	77	58/19	60.8±13.6	349	139/210	39.2±12.4	<i>TGF-β1</i>	rs1800470	CC vs CT	1.96 (1.06-3.64)	0.0312	Illumina GoldenGate bead SNP assay	0.517			
46	Xin-xia et	Han Chinese		170	85	68/17	62.4±9.5	85	68/17	61.9±9.4					PCR-RFLP	0.460				

	al. (2011) ⁴⁵		ATS/ERS criteria 2000							<i>PAI-1</i>	PAI-1 4G/5G	5G5G vs 4G5G+4 G4G	0.42 (0.19- 0.90)	0.02		-	
47	Yuan et al. (2011) ⁴⁶	Chinese	-	118	64	-	-	54	-	<i>CRI</i>	HindIII RFLP (intron 27)	L	4.47 (2.37- 8.44)	<0.05	PCR-RFLP	-	
48	Bourna zos et al. (2010) ⁴⁷	Caucasia n	BTS/Thor acic society of Australia/ New Zealand and the Irish Thoracic Society Interstitial lung disease guideline 2008	363	142	95/4 7	70.0±8.8	221	-	<i>FCGR3B</i>	> ² FCGR3B copies	-	1.91 (1.17- 3.12)	0.01	RT-PCR	-	
49	Aquin o- Gálvez et al. (2009) ⁴⁸	Mexican	ATS/ERS criteria 2000	281	80	42/3 8	64.8±11.0	201	72/1 29	<i>MICA</i>	MICA*00 1	MICA* 001	2.91 (1.04- 8.25)	0.03**	Reference strand mediated conformation analysis (RSCA)	-	
											MICA*00 4	MICA* 004	0.41 (0.20- 0.80)	0.008**		-	
											MICA*00 4/*004	MICA* 004/*00 4	0.17 (0.0 – 1.15)	0.04**		-	
											MICA*00 1/*00201	MICA* 001/*00 201	4.72 (1.15- 22.51)	0.01**		-	
50	Liu et al. (2009) ⁴⁹	Chinese	-	120	60	-	-	60	-	<i>ENA-78</i>	156G/C	C	4.23 (1.35- 13.20)	0.008	PCR-RFLP	-	
											<i>IP-10</i>	1596C/T	T	0.38 (0.15- 0.95)	0.031	-	
51	Mushir oda et al. (2008) ^{G50}	Japanese	ATS/ERS guideline s 2002	1711	242	183/ 59	67.0(42- 87)	1,46 9	948/ 521	-	<i>TERT</i>	rs2736100	A	1.81 (1.46- 2.23)*	2.9 × 10 ⁻⁸	Illumina HumanHap30 0 Bead Arrays and multiplex- PCR based Invader	0.496

															assay3 or TaqMan assay		
52	Checa et al. (2008) ⁵¹	Mexican	ATS/ERS criteria 2000	435	130	67/6 3	62.5±9.6	305	189/ 116	40.6±1 2.4	<i>MMP-1</i>	1G_1607_ 2G	2G	1.61 (1.13- 2.29)	0.0074~/ 0.006**	PCR-RFLP	-
				156	49 (smokers)	-	-	107 (smokers)	-	-	<i>MMP-1</i>	G755T	T	1.68 (1.01- 2.74)	0.048~/ 0.04**		-
53	Vasakova et al. (2006) ⁵²	Caucasian of Czech Republic	ATS/ERS criteria 2000	133	30	10/2 0	65.4(36- 85)	103	24/7 9	53.0(2 4-71)	<i>IL-4</i>	C33T	T	3.35 (1.74- 6.44)~	0.0003~	PCR	-
											<i>IL-4</i>	rs2243250	T	0.19 (0.10- 0.37)~	<0.0001~		0.469
54	Riha et al. (2004) ⁵³	Caucasian	ATS/ERS criteria 2000	162	22	17/5	60.0±14	140	-	-	<i>TNF-α</i>	A308G	A	3.29 (1.61- 6.70)~	0.001	PCR-RFLP	-
55	Zorzetto et al. (2003) ⁵⁴	Italian whites	ATS/ERS criteria 2002	240	74	51/2 3	66.5±10.9	166	105/ 61	61.7±8 .4	<i>CR1</i>	C5507G	G	2.38 (1.53- 3.69)~	0.0001~	PCR-RFLP	-
											<i>CR1</i>	C5507G	CC	0.45 (0.25- 0.78)	0.004		-
56	Selman et al. (2003) ⁵⁵	Mexican	ATS/ERS criteria 2000	248	54(non smokers)	-	-	194	124/ 70	41.0±1 4.5	<i>SP-A1</i>	SP-A1	6A ⁴	3.67 (1.34- 10.07)	0.01	PCR-RFLP	-
											<i>SP-A1</i>	SP-AA219	T	3.13 (1.18- 8.32)	0.02		-
											<i>SP-A1</i>	SP-AA50	C	6.68 (1.87- 23.86)	<0.01		-
											<i>SP-A1</i>	SP-AA62	G	3.34 (1.56- 7.14)	<0.01		-
				124	30(smokers)	-	-	194	124/ 70	41.0±1 4.5	<i>SP-B</i>	SP-B1580	C	7.63 (1.64- 35.4)	0.01		-
57	Libby et al. (1982) ⁵⁶	Caucasian	Patients evaluated with a medical history, physical examination, chest radiograph, pulmonary function tests, and lung biopsy.	220	20	11/9	57.2	200	-	-	<i>HLA-DR</i>	HLA-DR2	HLA-DR2	5.28 (2-13.96)~	0.0006	Two stage complement-dependent microlymphocytotoxicity assay	-

Legend: All studies include sporadic IPF cases only except Fingerlin et al., 2013³⁰ which include fibrotic IIPs as cases. In paper Allen et al., 2020³, sex data only available for 500 Chicago cases and 510 Chicago controls & age data available for 602 UK cases; in paper Allen et al., 2020³ & 2017,¹² age data available for 103 Chicago controls; In paper Fingerlin et al., 2013,³⁰ p-value is adjusted for sex; in paper Noth et al., 2013,³¹ sex data available for 370 & 90 cases in replication phase I & II respectively and age data is only available for 103 controls in discovery GWAS.

Global allele frequency of risk allele taken from dbSNP (1000 Genomes Project).⁵⁷

OR, odds ratio; CI, confidence interval; SNP, single nucleotide polymorphism; N, number; ATS, American Thoracic Society; ERS, European Respiratory Society; JRS, Japanese Respiratory Society; ALAT, Latin-American Thoracic association; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSP, sequence specific amplification.

ATS/ ERS guidelines 2000⁵⁸

ATS/ERS guidelines 2002⁵⁹

ATS/ERS criteria 2002**⁶⁰

ATS/ERS/JRS/ALAT guidelines 2011⁶¹

ATS/ERS guidelines 2013⁶²

ATS/ERS/JRS/ALAT guidelines 2018⁶³

BTS/Thoracic society of Australia/New Zealand and the Irish Thoracic Society Interstitial lung disease guideline 2008⁶⁴

^GGenome wide association study; ^DDiscovery cohort; ^RReplication cohort, ^MMeta-analysis; ~ calculated value; ** corrected p-value; * annotated rsid from dbSNP; ^a chicago consortium; ^b colorado consortium; ^y UK biobank; @ UUS; ^ genentech, * calculated value, “ allele frequency taken from ALFA.

Supplementary Table 5: Details of quality assessment scoring for studies included in the meta-analysis based on modified Newcastle Ottawa Scale (NOS).

SI. No .	Included studies	Selection				Comparability		Exposure		Total star
		Adequate case definition	Representativ e samples of cases	Appropriat e control selection	Controls are respiratory disease negative	Controls for Age	Controls for Gender	Assessment of outcome	Same method of ascertainment for cases and controls	
MUC5B										
1	Bonella et al. (2021)	*	*	*	*	-	*	*	*	- 7
2	Deng et al. (2019)	*	-	*	*	*	*	*	*	- 7
3	Dressen et al. (2018)	*	*	*	-	*	*	*	*	- 7
4	Dabar et al. (2018)	*	-	*	-	-	-	-	-	2
5	Allen et al. (2017)	*	-	*	*	*	*	*	-	- 6
6	Petrovski et al. (2017)	*	*	*	*	-	-	*	*	- 6
7	Kishore et al. (2016)	*	*	-	*	-	-	*	-	- 4
8	Van der Vis et al. (2015)	*	*	*	*	-	-	*	*	- 6
9	Horimasu et al. (2015)	*	*	*	*	-	-	*	*	- 6
10	Jiang et al. (2015)	*	*	*	*	*	*	*	*	- 8
11	Wang et al. (2014)	*	*	*	*	*	*	*	*	- 8
12	Coghlan et al. (2014)	*	*	*	-	*	-	*	-	- 5
13	Noth et al. (2013)	*	*	*	*	-	-	*	*	- 6
14	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	- 7
15	Wei et al. (2013)	*	*	*	*	-	-	*	*	- 6
16	Stock et al. (2013)	*	*	*	*	-	-	*	*	- 6
17	Borie et al. (2013)	*	*	*	-	-	-	*	*	- 5

18	Zhang et al. (2011)	*	*	*	*	-	-	*	*	-	6
TERT											
19	Guzmán- Vargas et al. (2021)	*	*	*	*	*	*	*	*	-	8
20	Arimura- Omori et al. (2020)	*	*	*	*	*	*	*	*	-	8
21	Dressen et al. (2018)	*	*	*	-	*	*	*	*	-	7
22	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4
23	Wei et al. (2013)	*	*	*	*	-	-	*	*	-	6
24	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
25	Mushiroda et al. (2008)	*	*	*	-	-	-	*	*	-	5
FAM13A											
26	Guzmán- Vargas et al. (2021)	*	*	*	*	*	*	*	*	-	8
27	Hirano et al. (2016)	*	*	*	*	-	-	*	*	-	6
28	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4
29	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
DSP											
30	Guzmán- Vargas et al. (2021)	*	*	*	*	*	*	*	*	-	8
31	Allen et al. (2017)	*	-	*	*	*	*	*	-	-	6
32	Noth et al. (2013)	*	*	*	*	-	-	*	*	-	6
33	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	-	7
DPP9											
34	Allen et al. (2017)	*	-	*	*	*	*	*	-	-	6
35	Kishore et al. (2016)	*	*	-	*	-	-	*	-	-	4

36	Fingerlin et al. (2013)	*	*	*	-	*	*	*	*	*	-	7
TGF-β1												
37	Deng et al. (2019)	*	-	*	*	*	*	*	*	*	-	7
38	Zhang et al. (2015)	*	*	*	*	-	-	*	*	-	-	6
39	Son et al. (2013)	*	*	*	*	-	*	*	*	-	-	7
40	Alhamad et al. (2013)	*	*	*	*	-	-	*	*	-	-	6
41	Xin-xia et al. (2011)	*	*	*	*	*	*	*	*	-	-	8
42	Xaubet et al. (2003)	*	-	-	*	-	-	*	*	-	-	4

Legend: The modified Newcastle-Ottawa Scale (NOS) assesses the study quality in 3 categories: selection, comparability, and exposure. A maximum of 4 stars (*) could be given to selection items, 2 stars to comparability section and 3 stars to Exposure category.

Supplementary Table 6: Summary of subgroup analysis findings based on ethnicity between IPF patients and healthy controls for genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), e) rs1800470 (*TGF- β 1*).

SI. No.	Genetic variant (Gene)	Sub-group	Number of studies (N)	Heterogeneity		OR (95% CI)
				I ² (%)	p-value	
1	rs35705950 (<i>MUC5B</i>)	Asian	4	17.97	0.549	2.54 (0.78-4.31)
		European	14	81.93	0.00	3.97 (3.52-4.60)
2	rs2736100 (<i>TERT</i>)	Asian	2	0.00	0.85	0.56 (0.46-0.65)
		European	5	0.00	0.08	0.74 (0.70-0.79)
3	rs2609255 (<i>FAM13A</i>)	Asian	1	-	-	2.01 (1.22-2.80)
		European	3	16.35	0.31	1.36 (1.27-1.47)
4	rs1800470 (<i>TGF-β1</i>)	Asian	4	57.32	0.025	1.07 (0.75-1.39)
		European	1	-	-	0.95 (0.62-1.29)
		Others	1	-	-	1.42 (0.79-2.06)

Legend: OR, Odds ratio; CI, Confidence interval; N, Number. All calculations were done using Stata/MP 16.0.

All p values calculated using chi-square test.


Supplementary Table 7: Sensitivity analysis with pooled odds ratios (OR) for studies exploring the association of genetic variants with IPF susceptibility by removing one study each time.

Genetic variant (Gene)	Study omitted (Author & Year)	OR (95% CI)	p-value	Heterogeneity		Model	Egger's test	
				I ² (%)	p-value		Z-score	p-value
rs35705950 (<i>MUC5B</i>)	Bonella et al. (2021)	3.83 (3.21-4.45)	0.00	82.68	0.00	R	1.38	0.17
	Deng et al. (2019)	3.85 (3.23-4.47)	0.00	82.64	0.00	R	1.58	0.11
	Dressen et al. (2018)	3.76 (3.13-4.40)	0.00	80.00	0.00	R	1.75	0.08
	Allen et al. (2017)	3.72 (3.11-4.32)	0.00	79.71	0.00	R	1.68	0.09
	Petrovski et al. (2017)	3.85 (3.20-4.50)	0.00	83.03	0.00	R	1.48	0.14
	Kishore et al. (2016)	3.81 (3.19-4.44)	0.00	82.63	0.00	R	1.35	0.18
	Van der Vis et al. (2015)	3.87 (3.22- 4.52)	0.00	83.12	0.00	R	1.49	0.13
	Horimasu et al. (2015) I	3.85 (3.23-4.47)	0.00	82.66	0.00	R	1.61	0.11
	Horimasu et al. (2015) II	3.84 (3.23-4.46)	0.00	82.58	0.00	R	1.26	0.21
	Jiang et al. (2015)	3.99 (3.38-4.59)	0.00	78.82	0.00	R	1.34	0.18
	Wang et al. (2014)	3.85 (3.22-4.47)	0.00	82.85	0.00	R	1.50	0.13
	Coghlan et al. (2014)	3.93 (3.29-4.57)	0.00	82.16	0.00	R	1.46	0.14
	Noth et al. (2013) I	4.01 (3.44-4.59)	0.00	72.91	0.00	R	1.14	0.26
	Noth et al. (2013) II	3.88 (3.22-4.54)	0.00	82.80	0.00	R	1.46	0.15
	Noth et al. (2013) III	3.93 (3.29-4.59)	0.00	81.82	0.00	R	1.41	0.16
	Fingerlin et al. (2013)	3.81 (3.15-4.46)	0.00	80.47	0.00	R	1.64	0.10
	Wei et al. (2013)	3.90 (3.25-4.55)	0.00	82.84	0.00	R	1.47	0.14
	Stock et al. (2013)	3.79 (3.16-4.42)	0.00	82.44	0.00	R	1.41	0.16
	Borie et al. (2013)	3.72 (3.13-4.31)	0.00	79.25	0.00	R	1.55	0.12
	Zhang et al. (2011) I	3.84 (3.194.49)	0.00	83.04	0.00	R	1.47	0.14
	Zhang et al. (2011) II	3.82 (3.18-4.47)	0.00	82.88	0.00	R	1.46	0.14
rs2736100 (<i>TERT</i>)	Guzmán-Vargas et al. (2021)	0.72 (0.62-0.82)	0.00	72.31	0.00	R	1.91	0.06
	Arimura-Omori et al. (2020)	0.72 (0.62-0.82)	0.00	73.10	0.00	R	1.54	0.12
	Dressen et al. (2018)	0.70 (0.58-0.81)	0.00	73.14	0.00	R	1.74	0.08
	Kishore et al. (2016)	0.68 (0.60-0.76)	0.00	66.25	0.01	R	-0.06	0.95
	Wei et al. (2013)	0.68 (0.59-0.78)	0.00	69.84	0.00	R	1.06	0.29
	Fingerlin et al. (2013) I	0.70 (0.58-0.82)	0.00	75.36	0.00	R	1.65	0.09

	Fingerlin et al. (2013) II	0.69 (0.58-0.81)	0.00	76.59	0.00	R	1.55	0.12
	Mushiroda et al. (2008)	0.73 (0.68-0.77)	0.00	0.01	0.03	R	1.29	0.20
rs2609255 (FAM13A)	Guzmán-Vargas et al. (2021)	1.36 (1.26-1.46)	0.00	44.55	0.14	F	0.81	0.423
	Kishore et al. (2016)	1.38 (1.28-1.48)	0.00	36.19	0.20	F	1.98	0.05
	Hirano et al. (2016)	1.36 (1.25-1.46)	0.00	16.35	0.31	F	0.27	0.79
	Fingerlin et al. (2013) I	1.45 (1.28-1.61)	0.00	36.97	0.19	F	0.60	0.55
	Fingerlin et al. (2013) II	1.33 (1.21-1.45)	0.009	38.45	0.18	F	1.12	0.26
rs2076295 (DSP)	Guzmán-Vargas et al. (2021)	1.45 (1.28-1.63)	0.00	76.94	0.01	R	-0.18	0.86
	Allen et al. (2017)	1.23 (0.88-1.57)	0.00	93.00	0.00	R	-2.99	0.00
	Noth et al. (2013)	1.34 (0.94-1.74)	0.00	94.99	0.00	R	-1.71	0.09
	Fingerlin et al. (2013) I	1.28 (0.87-1.68)	0.00	93.21	0.00	R	-2.81	0.05
	Fingerlin et al. (2013) II	1.26 (0.86-1.65)	0.00	94.03	0.00	R	-1.64	0.10
rs12610495 (DPP9)	Allen et al. (2017)	1.28 (1.19-1.36)	0.00	0.00	0.69	F	-0.25	0.80
	Kishore et al. (2016)	1.30 (1.22-1.38)	0.00	0.00	0.55	F	1.08	0.28
	Fingerlin et al. (2013) I	1.33 (1.22-1.45)	0.00	0.00	0.69	F	-0.72	0.47
	Fingerlin et al. (2013) II	1.28 (1.19-1.37)	0.00	0.00	0.15	F	-0.05	0.96
rs1800470 (TGF- β 1)	Deng et al. (2019)	0.96 (0.78-1.13)	0.00	41.66	0.14	F	2.11	0.03
	Zhang et al. (2015)	1.11 (0.78-1.445)	0.00	63.80	0.03	R	2.69	0.007
	Son et al. (2013)	1.04 (0.79 – 1.29)	0.00	61.20	0.04	R	2.40	0.02
	Alhamad et al. (2013)	1.03 (0.79-1.27)	0.00	59.01	0.05	R	2.30	0.02
	Xin-xia et al. (2011)	1.14 (0.95-1.33)	0.00	18.02	0.31	F	1.83	0.07
	Xaubet et al. (2003)	1.12 (0.83-1.41)	0.00	53.53	0.03	R	2.53	0.01

Legend: Bold characters highlight significantly associated alleles with respective p-values. OR, Odds ratio; CI, Confidence interval; R, Random effect model (maximum likelihood method); F, Fixed effect model (inverse-variance method); N, Number. All calculations were done using Stata/MP 16.0. All p values were calculated using the chi-square test.

Supplementary Fig. 2: Funnel plots showing publication bias among studies exploring IPF risk associated with genetic variants- a) rs35705950 (*MUC5B*), b) rs2736100 (*TERT*), c) rs2609255 (*FAM13A*), d) rs2076295 (*DSP*), e) rs12610495 (*DPP9*), f) rs1800470 (*TGF- β 1*). Each point – represents a separate study for the indicated association or natural logarithm (log) of OR. A horizontal line means effect size.



REFERENCES

1. Dhindsa RS, Mattsson J, Nag A, Wang Q, Wain LV, Allen R, et al. Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis. *Commun. Biol.* 2021; 4(1): 1-8.
2. Bonella F, Campo I, Zorzetto M, Boerner E, Ohshima S, Theegarten D, et al. Potential clinical utility of MUC5B und TOLLIP single nucleotide polymorphisms (SNPs) in the management of patients with IPF. *Orphanet J. Rare Dis.* 2021; 16(1).
3. Allen RJ, Guillen-Guio B, Oldham JM, Ma SF, Dressen A, Paynton ML, et al. Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2020; 201(5): 564–74.
4. Arimura-Omori M, Kiyohara C, Yanagihara T, Yamamoto Y, Ogata-Suetsugu S, Harada E, et al. Association between telomere-related polymorphisms and the risk of IPF and COPD as a precursor lesion of lung cancer: Findings from the fukuoka tobacco-related lung disease (fold) registry. *Asian Pac. J. Cancer Prev.* 2020; 21(3): 667–73.
5. Moore C, Blumhagen RZ, Yang I v., Walts A, Powers J, Walker T, et al. Resequencing study confirms that host defense and cell senescence gene variants contribute to the risk of idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med.* 2019; 200(2): 199–208.
6. Liu J, Deng Y, Wang Z, Mo B, Wei J, Cheng Z, et al. A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese. *J. Clin. Lab. Anal.* 2021; 35(6): e23782.
7. Deng Y, Li Z, Liu J, Wang Z, Cao Y, Mou Y, et al. Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis. *Hum. Mutat.* 2018; 39(9): 1238–45.
8. Wang H, Zhuang Y, Peng H, Cao M, Li Y, Xu Q, et al. The relationship between MUC5B promoter, TERT polymorphisms and telomere lengths with radiographic extent and survival in a Chinese IPF cohort. *Sci. Rep.* 2019; 9(1): 1-7.
9. Lorenzo-Salazar JM, Ma SF, Jou J, Hou PC, Guillen-Guio B, Allen RJ, et al. Novel idiopathic pulmonary fibrosis susceptibility variants revealed by deep sequencing. *ERJ Open Res.* 2019; 5(2).

10. Dressen A, Abbas AR, Cabanski C, Reeder J, Ramalingam TR, Neighbors M, et al. Analysis of protein-altering variants in telomerase genes and their association with MUC5B common variant status in patients with idiopathic pulmonary fibrosis: a candidate gene sequencing study. *Lancet Respir. Med.* 2018; 6(8): 603–14.
11. Daniil Z, Kotsiou OS, Grammatikopoulos A, Peletidou S, Gkika H, Malli F, et al. Detection of mitochondrial transfer RNA (mt-tRNA) gene mutations in patients with idiopathic pulmonary fibrosis and sarcoidosis. *Mitochondrion*. 2018; 43: 43-52.
12. Allen RJ, Porte J, Braybrooke R, Flores C, Fingerlin TE, Oldham JM, et al. Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. *Lancet Respir. Med.* 2017; 5(11): 869–80.
13. Petrovski S, Todd JL, Durheim MT, Wang Q, Chien JW, Kelly FL, et al. An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis. *Am J Respir Crit Care Med.* 2017; 196(1): 82–93.
14. Hirano C, Ohshima S, Horimasu Y, Iwamoto H, Fujitaka K, Hamada H, et al. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. *Respir. Med.* 2017; 123: 105–9.
15. Yamaguchi K, Iwamoto H, Horimasu Y, Ohshima S, Fujitaka K, Hamada H, et al. AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis. *Respirology*. 2017; 22(5): 965-71.
16. Kishore A, Žižková V, Kocourková L, Petrкова J, Bouros E, Nunes H, et al. Association study for 26 candidate loci in idiopathic pulmonary fibrosis patients from four European populations. *Front. immunol.* 2016; 7: 274.
17. Van der Vis JJ, Snetselaar R, Kazemier KM, ten Klooster L, Grutters JC, van Moorsel CH. Effect of Muc5b promoter polymorphism on disease predisposition and survival in idiopathic interstitial pneumonias. *Respirology*. 2016; 21(4): 712–7.
18. Aquino-Gálvez A, González-Ávila G, Pérez-Rodríguez M, Partida-Rodríguez O, Nieves-Ramírez M, Piña-Ramírez I, et al. Analysis of heat shock protein 70 gene polymorphisms Mexican patients with idiopathic pulmonary fibrosis. *BMC Pulm. Med.* 2015; 15(1): 1-8.

19. Peljto AL, Selman M, Kim DS, Murphy E, Tucker L, Pardo A, et al. The MUC5B promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. *Chest*. 2015; 147(2): 460-4.
20. Zhang HP, Zou J, Xie P, Gao F, Mu HJ. Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis. *Kaohsiung J. Med. Sci.* 2015; 31: 613–20.
21. Zhang HT, Fang SC, Wang CY, Wang W, Wu J, Wang C, et al. MMP-9 1562C> T gene polymorphism and efficacy of glucocorticoid therapy in idiopathic pulmonary fibrosis patients. *Genet. Test. Mol. Biomark.* 2015; 19(11): 591-7.
22. Horimasu Y, Ohshima S, Bonella F, Tanaka S, Ishikawa N, Hattori N, et al. MUC5B promoter polymorphism in Japanese patients with idiopathic pulmonary fibrosis. *Respirology*. 2015; 20(3): 439–44.
23. Mathai SK, Pedersen BS, Smith K, Russell P, Schwarz MI, Brown KK, et al. Desmoplakin Variants Are Associated with Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med.* 2016; 193(10): 1151–60.
24. Jiang H, Hu Y, Shang L, Li Y, Yang L, Chen Y. Association between MUC5B polymorphism and susceptibility and severity of idiopathic pulmonary fibrosis. *Int. J. Clin. Exp. Pathol.* 2015; 8(11): 14953.
25. Wang C, Zhuang Y, Guo W, Cao L, Zhang H, Xu L, et al. Mucin 5B promoter polymorphism is associated with susceptibility to interstitial lung diseases in Chinese males. *PloS One*. 2014; 9(8): e104919.
26. Uh ST, Jang AS, Park SW, Park JS, Min CG, Kim YH, et al. ADAM33 gene polymorphisms are associated with the risk of idiopathic pulmonary fibrosis. *Lung*. 2014; 192(4): 525-32.
27. Sangiuolo F, Puxeddu E, Pezzuto G, Cavalli F, Longo G, Comandini A, et al. HFE gene variants and iron-induced oxygen radical generation in idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2015; 45(2): 483-90.

28. Coghlan MA, Shifren A, Huang HJ, Russell TD, Mitra RD, Zhang Q, et al. Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations. *BMJ Open Respir. Res.* 2014; 1(1).
29. Ohshima S, Horimasu Y, Bonella F, Iwamoto H, Ishikawa N, Fujitaka K, et al. Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis. *Eur. Respir. J.* 2014; 44.
30. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, et al. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat. Genet.* 2013; 45(6): 613–20.
31. Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: A genome-wide association study. *Lancet Respir. Med.* 2013; 1(4): 309–17.
32. Uh ST, Kim TH, Shim EY, Jang AS, Park SW, Park JS, et al. Angiotensin-converting enzyme (ACE) gene polymorphisms are associated with idiopathic pulmonary fibrosis. *Lung.* 2013; 191(4): 345–51.
33. Wei R, Li C, Zhang M, Jones-Hall YL, Myers JL, Noth I, et al. Association between MUC5B and TERT polymorphisms and different interstitial lung disease phenotypes. *Transl Res.* 2014; 163(5): 494–502.
34. Stock CJ, Sato H, Fonseca C, Banya WAS, Molyneaux PL, Adamali H, et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. *Thorax.* 2013; 68(5): 436–41.
35. Borie R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, et al. The MUC5B Variant Is Associated with Idiopathic Pulmonary Fibrosis but Not with Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population. *PLoS One.* 2013; 8(8).
36. Son JY, Kim SY, Cho SH, Shim HS, Jung JY, Kim EY, et al. TGF- β 1 T869C polymorphism may affect susceptibility to idiopathic pulmonary fibrosis and disease severity. *Lung.* 2013; 191(2): 199–205.

37. Martinelli M, Scapoli L, Carbonara P, Valentini I, Girardi A, Farinella F, et al. Idiopathic pulmonary fibrosis and polymorphisms of the folate pathway genes. *Clin. Biochem.* 2013; 46(1-2): 85-8.
38. Korthagen NM, van Moorsel CHM, Barlo NP, Kazemier KM, Ruven HJT, Grutters JC. Association between variations in cell cycle genes and idiopathic pulmonary fibrosis. *PLoS One.* 2012; 7(1).
39. Zhang J, Xu DJ, Xu KF, Wu B, Zheng MF, Chen JY, et al. HLA-A and HLA-B gene polymorphism and idiopathic pulmonary fibrosis in a Han Chinese population. *Respir. Med.* 2012; 106(10): 1456-62.
40. Zhang Y, Noth I, Garcia JGN, Kaminski N. A Variant in the Promoter of MUC5B and Idiopathic Pulmonary Fibrosis. *N. Engl. J. Med.* 2011; 364(16): 1576-7.
41. Ahn MH, Park BL, Lee SH, Park SW, Park JS, Kim DJ, et al. A promoter SNP rs4073T> A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. *Respir. Res.* 2011; 12(1): 1-7.
42. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. *N Engl J Med.* 2011; 364(16): 1503-12.
43. Xue J, Gochuico BR, Alawad AS, Feghali-Bostwick CA, Noth I, Nathan SD, et al. The HLA class II Allele DRB1* 1501 is over-represented in patients with idiopathic pulmonary fibrosis. *PloS One.* 2011; 6(2): e14715.
44. Barlo NP, van Moorsel CHM, Korthagen NM, Heron M, Rijkers GT, Ruven HJT, et al. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1 β in idiopathic pulmonary fibrosis. *Clin. Exp. Immunol.* 2011; 166: 346-51.
45. Li XX, Li N, Ban CJ, Zhu M, Xiao B, Dai HP. Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor- β 1 and plasminogen activator inhibitor 1. *Chin. Med. J.* 2011; 124(13): 1923-7.
46. Yuan YD, Zhao MX, Yu J. Association between genetic polymorphism of erythrocyte CR1 and the susceptibility of idiopathic pulmonary fibrosis. *Chinese Journal of Tuberculosis and Respiratory Diseases.* 2011; 34: 841-5.

47. Bournazos S, Bournazou I, Murchison JT, Wallace WA, McFarlane P, Hirani N, et al. Copy number variation of FCGR3B is associated with susceptibility to idiopathic pulmonary fibrosis. *Respiration*. 2011; 81(2): 142–9.
48. Aquino-Galvez A, Pérez-Rodríguez M, Camarena Á, Falfan-Valencia R, Ruiz V, Montaño M, et al. MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility. *Hum. Genet.* 2009; 125(5): 639-48.
49. Liu L, Dai HP, Xiao B, Zhang S, Ban CJ, Xin P. Association of ENA-78, IP-10 and VEGF gene polymorphism with idiopathic pulmonary fibrosis. *Zhonghua yi xue za zhi*. 2009; 89(38): 2690-4.
50. Mushirosa T, Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, Ogura T, et al. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. *J. Med. Genet.* 2008; 45(10): 654–6.
51. Checa M, Ruiz V, Montaño M, Velázquez-Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. *Hum. Genet.* 2008; 124(5): 465-72.
52. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. *Tissue Antigens*. 2006; 67(3): 229-32.
53. Riha RL, Yang IA, Rabnott GC, Tunnicliffe AM, Fong KM, Zimmerman PV. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. *J. Intern. Med.* 2004; 34(3): 126-9.
54. Zorzetto M, Ferrarotti I, Trisolini R, Agli LL, Scabini R, Novo M, et al. Complement receptor 1 gene polymorphisms are associated with idiopathic pulmonary fibrosis. *Am. J. Respir. Crit. Care Med.* 2003; 168(3): 330-4.
55. Selman M, Lin HM, Montaño M, Jenkins AL, Estrada A, Lin Z, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. *Hum. Genet.* 2003; 113: 542–50.

56. Libby DM, Gibofsky A, Fotino M, Waters SJ, Smith JP. Immunogenetic and clinical findings in idiopathic pulmonary fibrosis: association with the B-cell alloantigen HLA-DR2. *Am. Rev. Respir. Dis.* 1983; 127(5): 618-22.
57. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 2001; 29(1): 308-11.
58. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. *Am J Respir Crit Care Med.* 2000; 161: 646–664.
59. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2002; 165: 277–304.
60. Demedts M, Costabel U. ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Eur. Respir. J.* 2002; 19(5): 794-796
61. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *Am J Respir Crit Care Med.* 2011; 183: 788–824
62. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013; 188: 733–48.
63. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. *Am J Respir Crit Care Med.* 2018; 198(5): e44-68.
64. Bradley B, Branley HM, Egan JJ, Greaves MS, Hansell DM, Harrison NK, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. *Thorax.* 2008; 63: v1–v58.